Two patients exceed 14 months on treatment in Phase 2 trial of advanced ovarian cancerAllarity maintains a cash balance of $18.5 million, sufficient to advance and accelerate stenoparib’s clinical development toward FDA approval Expansion of Allarity Medical Laboratory into revenue-generating services for external biotech clientsContinued focus on advancing stenoparib to address critical unmet needs in ovarian cancer Boston (November 18, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASD ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share ALLR The Nasdaq Stock Market LLC Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☒ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30 ...

Exhibit 99.1 Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights - Cash balance at $18.5 million - Strengthened leadership team with new members driving stenoparib development - NASDAQ compliance regained Boston (November 14, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments using its proprietary, drug-specific patient selectio ...

NEW YORK, Nov. 09, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline. SO WHAT: If you purchased Allarity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...

NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline. SO WHAT: If you purchased Allarity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...

NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Allarity securities between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”). I ...

NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline. SO WHAT: If you purchased Allarity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...

NEW YORK, Nov. 02, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline. SO WHAT: If you purchased Allarity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...

NEW YORK, Nov. 1, 2024 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the "Class Period"), of the important November 12, 2024 lead plaintiff deadline.So what: If you purchased Allarity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.Wh ...

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the "Class Period"), of the important November 12, 2024 lead plaintiff deadline. SO WHAT: If you purchased Allarity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrange ...